Immucell AI Stock Analysis
Want to see ICCC full AI Analyst Report?
Immucell (ICCC) AI Stock Analysis
Immucell
(NASDAQ:ICCC)
ICCC’s score is driven primarily by improving financial performance (better profitability, stronger cash generation, and lower leverage) and a constructive earnings-call backdrop (strong growth and capacity expansion progress). These positives are tempered by a very high P/E valuation and largely neutral technical momentum, keeping the overall rating in the mid-range.
Immucell (ICCC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $97.63M
- Dividend Yield
- ―
- Average Volume (3M)
- 14.98K
- Price to Earnings (P/E)
- 53.8
- Beta (1Y)
- 0.09
- Revenue Growth
- 19.59%
- EPS Growth
- -20.08%
- Country
- US
- Employees
- 73
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Immucell Business Overview & Revenue Model
Company Description
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market...
How the Company Makes Money
ImmuCell makes money by selling animal health products to customers serving the cattle industry (including dairy-focused channels). Its core revenue stream historically has been product sales of its mastitis-related offering(s), sold through establis...
Immucell Earnings Call Summary
The call was strongly positive, characterized by 46% third-quarter revenue growth, improved gross margin, a return to profitability, higher manufacturing output, strong distributor and Tri-Shield growth, and progress on capacity expansion. The company also reported challenges, including historical contamination-related supply issues, rising colostrum-sourcing prices, higher operating expenses, and the unsuccessful Re-Tain development program, but these were outweighed by the reported operating and financial improvements.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects calf values to remain strong in 2027 and 2028, believes it can meet customer demand with improved yield management until the new drying capacity expansion project is completed, and expects the new freeze dryer planned for installation in the first half of 2027 to “triple or so” freeze-drying capacity; the liquids processing expansion is expected to be completed by the end of 2027, with the overall project remaining on track to the original $8 million overall budget.
Immucell Financial Statement Overview
Summary
Overall fundamentals are improving: a return to profitability in TTM, solid ~40% gross margin, sharply better operating cash flow ($7.8M) and free cash flow ($5.4M), and meaningfully reduced debt ($5.5M vs. ~$13–15M in prior years). Offsetting this, profitability is still thin (TTM net margin ~2.6%, EBIT margin ~3.8%) and results have been volatile across recent years, so durability of the recovery remains the key risk.
Income Statement
62PositiveBalance Sheet
70PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.21M | 27.64M | 26.49M | 17.47M | 18.57M | 19.24M |
| Gross Profit | 13.56M | 11.45M | 7.94M | 4.40M | 7.65M | 8.66M |
| EBITDA | 4.48M | 2.14M | 1.07M | -2.50M | 349.99K | 2.70M |
| Net Income | 1.88M | -1.04M | -2.16M | -5.77M | -2.49M | -78.29K |
Balance Sheet | ||||||
| Total Assets | 47.96M | 42.53M | 45.10M | 43.81M | 44.86M | 44.47M |
| Cash, Cash Equivalents and Short-Term Investments | 7.91M | 3.81M | 3.76M | 978.74K | 5.79M | 10.19M |
| Total Debt | 12.01M | 13.19M | 15.10M | 16.69M | 12.48M | 10.27M |
| Total Liabilities | 15.18M | 15.48M | 17.58M | 18.82M | 14.48M | 11.89M |
| Stockholders Equity | 32.77M | 27.06M | 27.52M | 24.99M | 30.38M | 32.58M |
Cash Flow | ||||||
| Free Cash Flow | 5.40M | 1.22M | -107.82K | -6.57M | -5.52M | -1.65M |
| Operating Cash Flow | 7.83M | 2.48M | 357.90K | -4.67M | -1.54M | 954.17K |
| Investing Cash Flow | -2.41M | -1.21M | -461.23K | -1.89M | -3.96M | -1.60M |
| Financing Cash Flow | -1.39M | -1.21M | 2.88M | 1.75M | 1.11M | 3.88M |
Immucell Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICCC, the sentiment is Positive. The current price of 10.75 is above the 20-day moving average (MA) of 10.32, above the 50-day MA of 10.10, and above the 200-day MA of 9.05, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 59.43 is Neutral, neither overbought nor oversold. The STOCH value of 73.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ICCC.
Immucell Risk Analysis
Immucell disclosed 38 risk factors in its most recent earnings report. Immucell reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksImmucell Peers Comparison
Overall Rating
ICCC63Neutral
INO55Neutral
ARCT54Neutral
PDSB42Neutral
RANI42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 63Neutral | $97.73M | 53.75 | 6.25% | ― | 19.59% | -20.08% | |
| 55Neutral | $267.85M | -1.80 | -9999.00% | ― | 63.93% | 68.94% | |
| 54Neutral | $240.96M | -2.70 | -46.79% | ― | -74.84% | -25.04% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | $91.63M | -1.56 | -679.00% | ― | ― | 32.24% | |
| 42Neutral | $73.40M | -2.78 | -96.44% | ― | 448.67% | 76.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ICCC | Immucell | 10.75 | 5.84 | 118.94% | |
| INO | Inovio Pharmaceuticals | 1.43 | -0.55 | -27.78% | |
| ARCT | Arcturus Therapeutics | 8.36 | 1.60 | 23.67% | |
| XBIT | XBiotech Inc. | 1.96 | -0.51 | -20.65% | |
| PDSB | Pds Biotechnology | 0.87 | 0.09 | 12.23% | |
| RANI | Rani Therapeutics Holdings, Inc. Class A | 0.53 | -1.41 | -72.89% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
